Hepatitis C virus and non-Hodgkin's lymphoma: findings from the Swiss HIV Cohort Study
14th Nov 2006, 18:30 GMT
S Franceschi, J Polesel, M Rickenbach, L Dal Maso, N M Probst-Hensch, C Fux, M Cavassini, B Hasse, A Kofler, B Ledergerber, P Erb & G M Clifford
Hepatitis C virus and non-Hodgkin's lymphoma: findings from the Swiss HIV Cohort Study related news:
- Simian Viral Strain Most Similar To HIV Found In Wild Gorilla Populations, Study Says — Health News from Medical News Today
- Volume 194, number 12: Treatment Benefit on Cerebrospinal Fluid HIV-1 Levels in the Setting of Systemic Virological Suppression and Failure — J Infect Dis Latest Issue
- Wild gorillas carriers of a SIV virus close to the AIDS virus — EurekAlert! - Breaking News
- Wild gorillas carriers of an SIV virus close to the AIDS virus — EurekAlert! - Medicine and Health
- Treat HIV-Positive Addicts To Slow AIDS In Russia, Stanford Study Says — Health News from Medical News Today
- Progress Made In HIV Vaccine Development — ScienceDaily Headlines: Health & Medicine
- Volume 194, number 12: A Complete Mutational Fitness Map of the Hepatitis C Virus Nonstructural 3 Protease: Relation to Recognition by Cytotoxic T Lymphocytes — J Infect Dis Latest Issue
- Nigeria: Know Your HIV Status, Muslim Youths Advised — AllAfrica News: HIV-Aids and STDs
- Volume 194, number 12: Equal Amounts of Intracellular and Virion-Enclosed Hepatitis C Virus RNA Are Associated with Peripheral-Blood Mononuclear Cells In Vivo — J Infect Dis Latest Issue
- Patients respond to health recall — BBC News | UK News | England | West Midlands | World Edition
Latest news from British Journal of Cancer AOP:
- Dairy products, calcium and prostate cancer risk
- Stressful life events and cancer risk
- A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens
- Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp
- Histamine, a vasoactive agent with vascular disrupting potential, improves tumour response by enhancing local drug delivery
- Perinatal factors, growth and development, and osteosarcoma risk